Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology

Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology

Wed, August 5, 2026 at 5:48 PM GMT+3 2 min read

• VVOS -5.46%
• RDGL -2.51%

The newly issued patent broadens intellectual property protection for Vivos' flagship oral medical device platform, reinforcing its competitive position in the obstructive sleep apnea treatment market.

Key Investor Takeaways

• Vivos Therapeutics (NASDAQ:VVOS) received a new U.S. patent that expands intellectual property protection for its Vivos CARE oral medical device technology.

• The new patent complements an earlier patent, creating broader protection that the company says is more difficult for competitors to design around.

• The strengthened patent portfolio supports Vivos' FDA-cleared Vivos CARE devices for treating severe obstructive sleep apnea in adults and moderate-to-severe obstructive sleep apnea in children.

• Management believes the expanded patent coverage reinforces the company's competitive positioning as it commercializes its sleep apnea technologies.

• The announcement focuses on intellectual property expansion rather than new financial results or commercial agreements.

Why VVOS Stock Is in Focus

Vivos Therapeutics (NASDAQ:VVOS) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,697,190, covering aspects of its Vivos CARE oral medical device technology used to treat obstructive sleep apnea (OSA).

The newly issued patent is a continuation of U.S. Patent No. 12,048,608, granted in 2024. According to the company, the two patents provide layered protection, with the earlier patent covering specific structural designs while the new patent broadens protection around the underlying technology. Vivos believes this combination creates stronger intellectual property barriers for competing products.

The company noted that its Vivos CARE devices previously received two FDA 510(k) clearances covering severe OSA in adults and moderate-to-severe OSA in children between the ages of six and 17. Vivos stated these remain the only oral appliances to receive those specific FDA clearances.

Chief Executive Officer Kirk Huntsman said the expanded patent portfolio reflects the company's continued investment in protecting its technology and strengthening its competitive position.

Why This Matters for Investors

While the announcement does not include new financial or operating results, intellectual property protection can be an important strategic asset for medical device companies.

Broader patent coverage may strengthen Vivos' ability to defend its technology, support product differentiation, and potentially reduce the risk of competing products using similar designs. For investors, this could reinforce the company's long-term commercialization strategy around its flagship Vivos CARE platform.

The value of the patent expansion will ultimately depend on the company's ability to continue growing adoption of its FDA-cleared devices and translate its intellectual property portfolio into sustained commercial performance.

What to Watch Next

Investors will likely monitor:

• Commercial adoption of the Vivos CARE platform following its FDA clearances.

• Additional intellectual property developments that further strengthen the company's technology portfolio.

• Progress expanding partnerships and commercialization efforts for obstructive sleep apnea treatment.

• Future updates on revenue growth, patient adoption, and execution of the company's broader sleep healthcare strategy.

Vivos Therapeutics stock price